EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors

Kuojun Zhang, Ke Ye, He Tang, Zhihao Qi, Tianyu Wang, Jie Mao, Xiangyu Zhang iD, Sheng Jiang iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.2c01800 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Kuojun Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Autoimmune Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 176 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Government of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinases (JAKs) are central components in cytokine signaling pathways. A number of small molecule JAK inhibitors have been approved to treat a wide range of inflammatory and autoimmune diseases. Due to safety concerns of pan-JAK inhibition, the thrust of current research is toward the discovery of isoform-selective JAK inhibitors. Selective inhibition of tyrosine kinase 2 (TYK2) has the potential to balance efficacy and safety. Substantial efforts have been made to develop selective TYK2 inhibitors: Deucravacitinib (BMS-986165) is a representative allosteric inhibitor that has been approved by the FDA, and ropsacitinib (PF-06826647) is an active site-directed inhibitor currently being evaluated in clinical trials. Herein, we outline the key roles of TYK2 in diseases, review the advances of selective TYK2 inhibitors, and finally discuss future perspectives and challenges in the development of TYK2 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsAutoimmune DiseasesHumansTYK2 KinaseJanus KinasesPyrazinesPyrazoles

Substanzen

TYK2 KinaseJanus Kinase InhibitorsJanus KinasesropsacitinibPyrazinesPyrazoles

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

ORCID-Profile: Xiangyu Zhang, Sheng Jiang

Förderung

  • China Postdoctoral Science Foundation
  • Government of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, K., Ye, K., Tang, H., Qi, Z., Wang, T., Mao, J., Zhang, X., & Jiang, S. (2023). Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01800

Vancouver

Zhang K, Ye K, Tang H, Qi Z, Wang T, Mao J, et al. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01800

BibTeX
@article{Zhang2023,
  author = {Zhang, Kuojun and Ye, Ke and Tang, He and Qi, Zhihao and Wang, Tianyu and Mao, Jie and Zhang, Xiangyu and Jiang, Sheng},
  title = {Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.2c01800}
}
Kostenlos starten →